Molecular classification and risk stratifiCation

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Studies over the past decade have greatly improved our understanding of the molecular basis of multiple myeloma and mechanisms of disease progression. Initial studies in myeloma, as with other hematological malignancies, depended solely on metaphase cytogenetics [1–5]. While this methodology was critical in the early studies of the disease, less than a third of the patients had bone marrow cytogenetic studies that were informative, primarily a reflection of the low proliferative state of the malignant plasma cells [6–8]. This was followed by the development of interphase FISH (fluorescent in situ hybridization), which did not depend on dividing cells for detection of abnormalities [9, 10]. With universal adoption of FISH studies, it became clear that nearly all patients with myeloma had genetic abnormalities that could be detected using FISH [11, 12]. Further refinement of the FISH techniques allowed simultaneous detection of the plasma cells, either by using markers for plasma cells or by performing FISH testing on sorted plasma cells, thus ensuring that the abnormality detected was unique to the plasma cells. Development of high-density oligonucleotide arrays allowed assessment of gene expression in tumor cells, and development of this technology provided an unprecedented look into the plasma cell biology, and better appreciation of the genetic heterogeneity that is the hallmark of this disease [13–18]. More recently, cutting edge genomic techniques including RNA sequencing, array CGH, SNP arrays, and whole genome sequencing have all been applied to myeloma allowing us to dissect the molecular complexity of this disease. A better appreciation of the heterogeneity uncovered by these assays have in turn led to several attempts at classifying the disease into groups that have implications on the disease outcome as well as best decisions regarding the best treatment approaches [19].

Original languageEnglish (US)
Title of host publicationMultiple Myeloma: Diagnosis and Treatment
PublisherSpringer New York
Pages55-64
Number of pages10
ISBN (Print)9781461485209, 9781461485193
DOIs
StatePublished - Jan 1 2014

Fingerprint

Plasma Cells
Fluorescence In Situ Hybridization
Cytogenetics
Naphazoline
RNA Sequence Analysis
Genetic Heterogeneity
Interphase
Hematologic Neoplasms
Metaphase
Oligonucleotide Array Sequence Analysis
Multiple Myeloma
Single Nucleotide Polymorphism
Cell Biology
Disease Progression
Bone Marrow
Genome
Technology
Gene Expression
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Molecular classification and risk stratifiCation. / Kumar, Shaji K; Fonseca, Rafael; Stewart, Alexander Keith.

Multiple Myeloma: Diagnosis and Treatment. Springer New York, 2014. p. 55-64.

Research output: Chapter in Book/Report/Conference proceedingChapter

Kumar, SK, Fonseca, R & Stewart, AK 2014, Molecular classification and risk stratifiCation. in Multiple Myeloma: Diagnosis and Treatment. Springer New York, pp. 55-64. https://doi.org/10.1007/978-1-4614-8520-9_6
Kumar SK, Fonseca R, Stewart AK. Molecular classification and risk stratifiCation. In Multiple Myeloma: Diagnosis and Treatment. Springer New York. 2014. p. 55-64 https://doi.org/10.1007/978-1-4614-8520-9_6
Kumar, Shaji K ; Fonseca, Rafael ; Stewart, Alexander Keith. / Molecular classification and risk stratifiCation. Multiple Myeloma: Diagnosis and Treatment. Springer New York, 2014. pp. 55-64
@inbook{9de888f1de454736a7acf002f4827fc3,
title = "Molecular classification and risk stratifiCation",
abstract = "Studies over the past decade have greatly improved our understanding of the molecular basis of multiple myeloma and mechanisms of disease progression. Initial studies in myeloma, as with other hematological malignancies, depended solely on metaphase cytogenetics [1–5]. While this methodology was critical in the early studies of the disease, less than a third of the patients had bone marrow cytogenetic studies that were informative, primarily a reflection of the low proliferative state of the malignant plasma cells [6–8]. This was followed by the development of interphase FISH (fluorescent in situ hybridization), which did not depend on dividing cells for detection of abnormalities [9, 10]. With universal adoption of FISH studies, it became clear that nearly all patients with myeloma had genetic abnormalities that could be detected using FISH [11, 12]. Further refinement of the FISH techniques allowed simultaneous detection of the plasma cells, either by using markers for plasma cells or by performing FISH testing on sorted plasma cells, thus ensuring that the abnormality detected was unique to the plasma cells. Development of high-density oligonucleotide arrays allowed assessment of gene expression in tumor cells, and development of this technology provided an unprecedented look into the plasma cell biology, and better appreciation of the genetic heterogeneity that is the hallmark of this disease [13–18]. More recently, cutting edge genomic techniques including RNA sequencing, array CGH, SNP arrays, and whole genome sequencing have all been applied to myeloma allowing us to dissect the molecular complexity of this disease. A better appreciation of the heterogeneity uncovered by these assays have in turn led to several attempts at classifying the disease into groups that have implications on the disease outcome as well as best decisions regarding the best treatment approaches [19].",
author = "Kumar, {Shaji K} and Rafael Fonseca and Stewart, {Alexander Keith}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-1-4614-8520-9_6",
language = "English (US)",
isbn = "9781461485209",
pages = "55--64",
booktitle = "Multiple Myeloma: Diagnosis and Treatment",
publisher = "Springer New York",

}

TY - CHAP

T1 - Molecular classification and risk stratifiCation

AU - Kumar, Shaji K

AU - Fonseca, Rafael

AU - Stewart, Alexander Keith

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Studies over the past decade have greatly improved our understanding of the molecular basis of multiple myeloma and mechanisms of disease progression. Initial studies in myeloma, as with other hematological malignancies, depended solely on metaphase cytogenetics [1–5]. While this methodology was critical in the early studies of the disease, less than a third of the patients had bone marrow cytogenetic studies that were informative, primarily a reflection of the low proliferative state of the malignant plasma cells [6–8]. This was followed by the development of interphase FISH (fluorescent in situ hybridization), which did not depend on dividing cells for detection of abnormalities [9, 10]. With universal adoption of FISH studies, it became clear that nearly all patients with myeloma had genetic abnormalities that could be detected using FISH [11, 12]. Further refinement of the FISH techniques allowed simultaneous detection of the plasma cells, either by using markers for plasma cells or by performing FISH testing on sorted plasma cells, thus ensuring that the abnormality detected was unique to the plasma cells. Development of high-density oligonucleotide arrays allowed assessment of gene expression in tumor cells, and development of this technology provided an unprecedented look into the plasma cell biology, and better appreciation of the genetic heterogeneity that is the hallmark of this disease [13–18]. More recently, cutting edge genomic techniques including RNA sequencing, array CGH, SNP arrays, and whole genome sequencing have all been applied to myeloma allowing us to dissect the molecular complexity of this disease. A better appreciation of the heterogeneity uncovered by these assays have in turn led to several attempts at classifying the disease into groups that have implications on the disease outcome as well as best decisions regarding the best treatment approaches [19].

AB - Studies over the past decade have greatly improved our understanding of the molecular basis of multiple myeloma and mechanisms of disease progression. Initial studies in myeloma, as with other hematological malignancies, depended solely on metaphase cytogenetics [1–5]. While this methodology was critical in the early studies of the disease, less than a third of the patients had bone marrow cytogenetic studies that were informative, primarily a reflection of the low proliferative state of the malignant plasma cells [6–8]. This was followed by the development of interphase FISH (fluorescent in situ hybridization), which did not depend on dividing cells for detection of abnormalities [9, 10]. With universal adoption of FISH studies, it became clear that nearly all patients with myeloma had genetic abnormalities that could be detected using FISH [11, 12]. Further refinement of the FISH techniques allowed simultaneous detection of the plasma cells, either by using markers for plasma cells or by performing FISH testing on sorted plasma cells, thus ensuring that the abnormality detected was unique to the plasma cells. Development of high-density oligonucleotide arrays allowed assessment of gene expression in tumor cells, and development of this technology provided an unprecedented look into the plasma cell biology, and better appreciation of the genetic heterogeneity that is the hallmark of this disease [13–18]. More recently, cutting edge genomic techniques including RNA sequencing, array CGH, SNP arrays, and whole genome sequencing have all been applied to myeloma allowing us to dissect the molecular complexity of this disease. A better appreciation of the heterogeneity uncovered by these assays have in turn led to several attempts at classifying the disease into groups that have implications on the disease outcome as well as best decisions regarding the best treatment approaches [19].

UR - http://www.scopus.com/inward/record.url?scp=84961310615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961310615&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-8520-9_6

DO - 10.1007/978-1-4614-8520-9_6

M3 - Chapter

AN - SCOPUS:84961310615

SN - 9781461485209

SN - 9781461485193

SP - 55

EP - 64

BT - Multiple Myeloma: Diagnosis and Treatment

PB - Springer New York

ER -